PETALING JAYA: As the Covid-19 pandemic hype diminishes, Duopharma Biotech Bhd’s strong execution and consistent earnings growth should eventually lead to a re-rating.
Duopharma is seen as a proven defensive shelter amid financial and economic uncertainties.
For this year, analysts are confident that the group will achieve satisfactory growth led by the higher budget allocated for the healthcare industry and improved contribution from the insulin contract worth RM375mil over the next three years, which works out to about RM80mil per year.
...